Postmenopausal Osteoporosis Clinical Trial
Official title:
Pilot Study on the Epidemiology, Identification Rate and Treatment Penetration of Vertebral Fractures Due to Osteoporosis in Switzerland (SwOF)
In Switzerland, the prevalence of vertebral fractures in community- dwelling women is
unknown and the published data from the Swiss hospitals statistics represent only the tip of
the iceberg. In addition, the percentages of women correctly identified with vertebral
fractures due to osteoporosis and the treatment rate of these women with a drug proven to
reduce the risk of further fractures are unknown. Furthermore, it is not known whether the
prevalence of vertebral fractures differs between urban and rural areas or between mountain
areas and plain country, e.g. due to possible differences in sun exposure (vitamin D
production) and/ or in physical activity and/ or dietary habits.
Clinical signs and symptoms leading to the suspicion of vertebral fracture(s) lack either
sensitivity (wall-occiput distance) or specificity (rib-pelvis distance). Whether a
combination of both would improve sensitivity and specificity is unknown.
The gold standard for the diagnosis of vertebral fracture relies on antero-posterior and
lateral X-Rays of the thoracic and lumbar spine. Despite standardization of X-Ray readings,
a retrospective study of hospitalized elderly patients has shown that as many as 50% of the
radiographic reports failed to note the presence of moderate to severe vertebral fractures.
In a primary care setting, fewer than 2% of the women received diagnoses of osteoporosis or
vertebral fracture, although expected prevalence is 20% to 30% and appropriate drug
treatment was offered to only 36% of the diagnosed patients.
The recent availability of software for vertebral fracture assessment (VFA) coupled to DXA
measurements allows for the detection of vertebral deformities, which is critical for
management of osteoporosis, as the existence of such deformities substantially increases the
risk of subsequent fracture. Recently published results show that VFA allows the diagnosis
of a vertebral fracture. The sensitivity of VFA for detection of vertebral fractures
compared to expert radiologist reading of X-ray is excellent for grade 2 and 3 fractures,
ranging between 90-94%.
Examinations
- Community-dwelling women from a random sample (address lists may be chosen from public
and/ or private providers)
- Aged 65-79 yrs
- Written informed consent
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05902078 -
Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis
|
Phase 4 | |
Completed |
NCT05087030 -
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis
|
Phase 3 | |
Completed |
NCT01544894 -
Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis
|
Phase 4 | |
Completed |
NCT00377819 -
Study of Transitioning From Alendronate to Denosumab
|
Phase 3 | |
Completed |
NCT00381251 -
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
|
Phase 1 | |
Completed |
NCT00239629 -
Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial
|
Phase 4 | |
Completed |
NCT04026256 -
Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration
|
Phase 4 | |
Terminated |
NCT00529373 -
A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)
|
Phase 3 | |
Completed |
NCT00092014 -
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
|
Phase 3 | |
Recruiting |
NCT06079476 -
A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.
|
Phase 4 | |
Not yet recruiting |
NCT04719650 -
Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid
|
Phase 4 | |
Recruiting |
NCT02981732 -
CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome
|
N/A | |
Completed |
NCT01709110 -
VERtebral Fracture Treatment Comparisons in Osteoporotic Women
|
Phase 4 | |
Completed |
NCT01348243 -
Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis
|
Phase 3 | |
Completed |
NCT00541658 -
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
|
Phase 3 | |
Completed |
NCT00395395 -
Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women
|
Phase 1 | |
Completed |
NCT00247273 -
A Study of Monthly Risedronate for Osteoporosis
|
Phase 3 | |
Active, not recruiting |
NCT03720886 -
G56W1 in Women With Postmenopausal Osteoporosis
|
Phase 1/Phase 2 | |
Completed |
NCT01668589 -
Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis
|
N/A | |
Completed |
NCT04664959 -
A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis
|
Phase 3 |